ALSO NOTED: CytRx raises $37M; Japan approves Glaxo drugs; Cepheid test gets FDA OK; and much more...

> CytRx plans to raise $37 million in a private offering of shares. Release

> Japanese regulators have approved GlaxoSmithKline's Seretide/Advair Diskus and Arixtra bronchial asthma treatment. Report

> The FDA has OK'd Cepheid's rapid test to detect antibiotic-resistant bacteria, sending its shares to a 52-week high. Report

> A new study published in the Journal of the American Medical Association has concluded that patients in for-profit dialysis chains routinely get higher doses of the antianemia drug Epogen. Report

> A new bill being considered by Congress would ban pharmaceutical companies from advertising new drugs for two years after they hit the market. Report

And Finally... A Chinese herbal medicine has been used as a model for a new drug that has cured malaria in animal studies. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.